Abstracts tagged "Lupus nephritis"

Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 0915 • ACR Convergence 2023
IL-16+ Is Abundantly Expressed by Kidney-infiltrating Myeloid and Lymphoid Cells in Lupus Nephritis: A Spatially Resolved Multiplexed Approach
Alessandra Ida Celia¹, Xiaoping Yang², Hana Minsky², Silvia Malvica², Michelle Petri³, the Accelerating Medicines Partnership in RA/SLE⁴, Avi Rosenberg⁵ and Andrea Fava², ¹John Hopkins University of Medicine, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴Multiple, Multiple, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We previously discovered that IL-16 is the urinary protein most strongly correlated with histological activity in lupus nephritis (LN), followed by neutrophil degranulation products…
Abstract Number: 1480 • ACR Convergence 2023
Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region
Jamal Al-Saleh¹, Faisal Elbadawi¹, Rajaie Namas², Samar Al-Emadi³, Khalid A. Alnaqbi⁴, Humaid A. Al-Wahshi⁵, Amjad Alkadi⁶, Suad Hannawi⁷, Mohamed Hamouda⁸, Averyan Vasylyev⁸, Arwa Al-Shujairi⁸, Reem Al-Jayyousi⁹ and Munther Khamashta⁸, ¹Dubai Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ²Cleveland Clinic Abu Dhabi, Department of Rheumatology, Abu Dhabi, United Arab Emirates, ³Hamad Medical Corporation, Department of Rheumatology, Doha, Qatar, ⁴Tawam Hospital, Department of Rheumatology, Al Ain, United Arab Emirates, ⁵The Royal Hospital, Department of Rheumatology, Muscat, Oman, ⁶Ministry of Health, Kuwait, Kuwait, ⁷Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ⁸GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁹Mohamed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, United Arab Emirates, and Mediclinic Parkview, Dubai, United Arab Emirates
Background/Purpose: Data from limited studies of LN in the Gulf region suggest that LN manifests more severely in this region than in Caucasian populations, yet…
Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Joshua Skydel¹, Reshma Ramachandran², Sakinah Suttiratana², Joseph Ross², Joshua Wallach³ and Christopher Burns⁴, ¹Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Yale University, New Haven, CT, ³Emory University, Atlanta, GA, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
Abstract Number: 2326 • ACR Convergence 2023
Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
Emily Littlejohn¹, Salem Almaani², Vanessa Birardi³, Ernie Yap⁴ and Christopher Collins⁵, ¹Cleveland Clinic, Cleveland, OH, ²Ohio State University Medical Center, Columbus, OH, ³Aurinia Pharmaceuticals Inc, Edmonton, AB, Canada, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁵Formerly Aurinia Pharmaceuticals Inc., Copenhagen, Denmark
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis and is a mediator of progressive kidney damage. Early reductions in urine protein creatinine ratio…
Abstract Number: 0740 • ACR Convergence 2023
Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease
Shivani Garg¹, Brad Astor², S. Sam Lim³, Amish Raval², Weixiong Zhong², Sarah Panzer², Brad Rovin⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Emory University, Atlanta, GA, ⁴Ohio State University, Columbus, OH
Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…
Abstract Number: 0920 • ACR Convergence 2023
Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB
Xing Lyu¹, minghui li¹, ping zhang², Wei Wei³, victoria werth⁴ and Ming-Lin Liu⁵, ¹Tianjin Medical University, Tianjin, China, ²Beaumont Hospital Royal Oak, Royal Oak, MI, ³Tianjin Medical University General Hospital, Tianjin, China, ⁴University of Pennsylvania, Wynnewood, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening both skin lesions and systemic symptoms, i.e. lupus nephritis. We recently reported that UVB exposure…
Abstract Number: 1481 • ACR Convergence 2023
Racial Disparities in Lupus Nephritis: A Nationwide Analysis
Faria Sami¹, Shahzad Ahmed Sami², Augustine Manadan³ and Shilpa Arora¹, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²Trinity Health Oakland Hospital, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is a significant predictor of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Racial disparities are known to exist in SLE…
Abstract Number: 1652 • ACR Convergence 2023
Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders
Melicent Miller¹, Stephanie Slan¹, Rosalind Ramsey-Goldman², Rodlescia Sneed³, Candace Feldman⁴, Patrick Wildman¹, Tori Justin⁵, Lydia Oberholtzer⁵ and Joy Buie⁶, ¹Lupus Foundation of America, Washington, DC, ²Northwestern University, Chicago, IL, ³Wayne State University, Detroit, MI, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Sharp Insight, LLC, Montgomery County, MD, ⁶Lupus Foundation of America, York, SC
Background/Purpose: Black/African American people with lupus (PWL) experience greater disease prevalence and severity than White PWL. The need for more racial and ethnic diversity amongst…
Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
David Jayne¹, Eduardo Mysler², Zahir Amoura³, Patrick Gavin⁴, Erik Allman⁴, Cristina Di Poto⁴, Xiang Tian⁴, Sonja Hess⁴, Eszter Csomor⁵, Philip Brohawn⁴, Daniel Muthas⁵, Adam Platt⁶, Hussein Al-Mossawi⁶, Catharina Lindholm⁵ and Nicola Ferrari⁶, ¹University of Cambridge, Cambridge, United Kingdom, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
Abstract Number: 0781 • ACR Convergence 2023
Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Amit Saxena¹, Peter Izmirly², Jammie Law³, Cristina Sorrento³, H Michael Belmont⁴ and Jill Buyon⁵, ¹New York University Grossman School of Medicine, Rheumatology, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…
Abstract Number: 0921 • ACR Convergence 2023
SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis
Yevgeniya Gartshteyn¹, Leila Khalili², Laura Geraldino-Pardilla², Adam Mor³ and Anca Askanase⁴, ¹Columbia University Medical Center, New York, NJ, ²Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ³Columbia University, New York, NY, ⁴Columbia University Medical Center, New York, NY
Background/Purpose: Better understanding of the abnormal immune responses in lupus nephritis (LN) is fundamental to identifying new therapies. We previously reported that the adaptor protein…
Abstract Number: 1482 • ACR Convergence 2023
Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan
Takehiro Nakai¹, Sho Fukui², Takahiro Asano¹, Futoshi Iwata¹, Hiroki Ozawa³, Satoshi Kawaai¹, Yukihiko Ikeda⁴, Haruyuki Yanaoka¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁵, Kenichi YAMAGUCHI⁶ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Brigham and Women's Hospital, Boston, MA, ³Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁴St Luke's international hospital in Japan, Tokyo, Japan, ⁵Kyorin University School of Medicine, Yokohoma, Japan, ⁶St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Over the past several decades, the treatment of lupus has seen significant advancements, with the approval of belimumab in 2017, and anifrolumab in 2021.…
Abstract Number: 1693 • ACR Convergence 2023
Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Alice Horisberger¹, Alec Griffith¹, Arnon Arazi², Joshua Keegan¹, Kaitlyn Howard¹, Takanori Sasaki¹, Tusharkanti Ghosh³, Andrea Fava⁴, Jun Inamo⁵, John Pulford¹, Ekaterina Murzin¹, Brandon Hancock¹, Katie Preisinger⁶, Maria Gutierrez-Arcelus⁷, Thomas Eisenhaure⁸, Joel Guthridge⁹, Paul Hoover¹⁰, Maria Dall'Era¹¹, David Wofsy¹¹, Diane L. Kamen¹², Kenneth Kalunian¹³, Richard Furie¹⁴, H Michael Belmont¹⁵, Peter Izmirly⁶, Robert Clancy¹⁶, David Hildeman¹⁷, steve Woodle¹⁷, William Apruzzese¹⁸, Maureen McMahon¹⁹, Jennifer Grossman²⁰, Jennifer Barnas²¹, Fernanda Payan-Schober²², Mariko Ishimori²³, Accelerating Medicines Partnership Program RA SLE Network²³, Matthias Kretzler²⁴, Celine Berthier²⁴, Jeff Hodgin²⁴, Dawit Demeke²⁴, Chaim Putterman²⁵, Nir Hacohen⁸, Michael Brenner¹, Jennifer Anolik²¹, Anne Davidson²⁶, Judith James⁹, Soumya Raychaudhuri¹⁰, Michelle Petri²⁷, Jill Buyon¹⁶, Betty Diamond²⁶, The Accelerating Medicines Partnership In RA/SLE²⁸, Fan Zhang²⁹, James Lederer¹ and Deepak Rao¹⁰, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Broad Institute of MIT and Harvard, Melrose, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴Johns Hopkins University, Baltimore, MD, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶New York University School of Medicine, New York, NY, ⁷Boston Children's Hospital, Boston, MA, ⁸Broad Institute of MIT and Harvard, Cambridge, MA, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of California San Francisco, San Francisco, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of California San Diego, La Jolla, CA, ¹⁴Northwell Health, Manhasset, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶NYU Grossman School of Medicine, New York, NY, ¹⁷University of Cincinnati College of Medicine, Cincinnati, OH, ¹⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ¹⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Texas Tech University Health Sciences Center, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Albert Einstein College of Medicine, Bronx, NY, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁸multisites, multisites, ²⁹University of Colorado, Aurora, CO
Background/Purpose: Patients with lupus nephritis (LN) have variable responses to standard-of-care therapy, and a third of patients with class III, IV, or V show a…
Abstract Number: 2338 • ACR Convergence 2023
Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis
Maria Dall'Era¹, Juan Lichauco², Hsiang Chen³, Harold Gomez⁴, Michael Tee⁵, Caroline Arroyo⁶, Joung-Liang Lan⁷, Yao-Fan Fang⁸, Edmund Chang⁹, Noosha Yousefpour⁹, Julian Low⁹, Min Bao⁹, Qing Chang⁹, Jeannette Osterloh⁹, Ann Mongan⁹, Ted Yednock⁹, Dean Artis⁹, Yaisa Andrews-Zwilling⁹ and Henk-Andre Kroon⁹, ¹University of California San Francisco, San Francisco, CA, ²St. Luke’s Medical Center, Quezon City, Philippines, ³Tri-service General Hospital, Taipei City, Taiwan, ⁴Angeles University Foundation Medical Center, Pampanga, Philippines, ⁵Medical Center Manila and University of the Philippines Manila, Manila, Philippines, ⁶Iloilo Doctors Hospital, Iloilo City, Philippines, ⁷China Medical University Hospital, Taichung, Taiwan, ⁸Chang Gung Memorial Hospital, Linkou, Taiwan, ⁹Annexon Biosciences, Brisbane, CA
Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease involving glomerular deposition of immune complexes containing pathogenic anti-C1q antibodies, leading to C1q binding and activation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].